- Home
- ZTEK vs WHWK Comparison
ZTEK vs WHWK Comparison
Compare ZTEK & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTEK
- WHWK
- Stock Information
- Founded
- ZTEK 2008
- WHWK 2007
- Country
- ZTEK Canada
- WHWK United States
- Employees
- ZTEK N/A
- WHWK N/A
- Industry
- ZTEK Major Chemicals
- WHWK Biotechnology: Pharmaceutical Preparations
- Sector
- ZTEK Industrials
- WHWK Health Care
- Exchange
- ZTEK Nasdaq
- WHWK Nasdaq
- Market Cap
- ZTEK 91.6M
- WHWK 82.4M
- IPO Year
- ZTEK N/A
- WHWK N/A
- Fundamental
- Price
- ZTEK $1.01
- WHWK $1.99
- Analyst Decision
- ZTEK
- WHWK
- Analyst Count
- ZTEK 0
- WHWK 0
- Target Price
- ZTEK N/A
- WHWK N/A
- AVG Volume (30 Days)
- ZTEK 834.2K
- WHWK 115.5K
- Earning Date
- ZTEK 08-14-2025
- WHWK 08-07-2025
- Dividend Yield
- ZTEK N/A
- WHWK N/A
- EPS Growth
- ZTEK N/A
- WHWK N/A
- EPS
- ZTEK N/A
- WHWK N/A
- Revenue
- ZTEK $678,078.00
- WHWK $21,596,000.00
- Revenue This Year
- ZTEK N/A
- WHWK N/A
- Revenue Next Year
- ZTEK N/A
- WHWK N/A
- P/E Ratio
- ZTEK N/A
- WHWK N/A
- Revenue Growth
- ZTEK 2519.47
- WHWK N/A
- 52 Week Low
- ZTEK $0.50
- WHWK $1.39
- 52 Week High
- ZTEK $1.84
- WHWK $3.81
- Technical
- Relative Strength Index (RSI)
- ZTEK 63.78
- WHWK 66.97
- Support Level
- ZTEK $0.65
- WHWK $1.78
- Resistance Level
- ZTEK $1.07
- WHWK $2.04
- Average True Range (ATR)
- ZTEK 0.12
- WHWK 0.08
- MACD
- ZTEK 0.04
- WHWK 0.03
- Stochastic Oscillator
- ZTEK 62.90
- WHWK 85.29
About ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About WHWK Whitehawk Therapeutics Inc. Common Stock
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.